Clinical Trial Update: A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing symptomatic remission in schizophrenia using long-acting risperidone microspheres; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED